Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

International Multi-center Open-label Randomized Clinical Trial of Efficacy, Safety and Pharmacokinetics of BCD-100 (JSC "BIOCAD", Russia) Monotherapy Compared to Docetaxel as Second-line Therapy of Patients With Advanced Inoperable or Metastatic Non-small Cell Lung Cancer

NCT03288870 is registered in ClinicalTrials.gov with Biocad as lead sponsor.

NCT NCT03288870
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03288870 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
International Multi-center Open-label Randomized Clinical Trial of Efficacy, Safety and Pharmacokinetics of BCD-100 (JSC "BIOCAD", Russia) Monotherapy Compared to Docetaxel as Second-line Therapy of Patients With Advanced Inoperable or Metastatic Non-small Cell Lung Cancer
Lead sponsor
Biocad
Phase
Phase 2/3
Overall status
Unknown status
Start date
September 19, 2017
Completion date
August 10, 2021
Enrollment
218 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer stage iiib, non-small cell carcinoma of lung, tnm stage 4